MX2020013301A - Metodos y composiciones para prevenir o tratar calcifilaxis. - Google Patents
Metodos y composiciones para prevenir o tratar calcifilaxis.Info
- Publication number
- MX2020013301A MX2020013301A MX2020013301A MX2020013301A MX2020013301A MX 2020013301 A MX2020013301 A MX 2020013301A MX 2020013301 A MX2020013301 A MX 2020013301A MX 2020013301 A MX2020013301 A MX 2020013301A MX 2020013301 A MX2020013301 A MX 2020013301A
- Authority
- MX
- Mexico
- Prior art keywords
- preventing
- methods
- calciphylaxis
- treating
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682794P | 2018-06-08 | 2018-06-08 | |
| PCT/US2019/036139 WO2019237054A1 (en) | 2018-06-08 | 2019-06-07 | Methods and compositions for preventing or treating calciphylaxis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013301A true MX2020013301A (es) | 2021-05-12 |
Family
ID=68763971
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013301A MX2020013301A (es) | 2018-06-08 | 2019-06-07 | Metodos y composiciones para prevenir o tratar calcifilaxis. |
| MX2024010211A MX2024010211A (es) | 2018-06-08 | 2020-12-07 | Metodos y composiciones para prevenir o tratar calcifilaxis. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024010211A MX2024010211A (es) | 2018-06-08 | 2020-12-07 | Metodos y composiciones para prevenir o tratar calcifilaxis. |
Country Status (11)
| Country | Link |
|---|---|
| US (7) | US10736858B2 (https=) |
| EP (1) | EP3801478A4 (https=) |
| JP (1) | JP2021527129A (https=) |
| KR (1) | KR20210018422A (https=) |
| CN (1) | CN112955131A (https=) |
| AU (1) | AU2019282421B2 (https=) |
| CA (1) | CA3102979A1 (https=) |
| IL (1) | IL279246B2 (https=) |
| MX (2) | MX2020013301A (https=) |
| SG (1) | SG11202012055PA (https=) |
| WO (1) | WO2019237054A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019237054A1 (en) | 2018-06-08 | 2019-12-12 | Epizon Pharma, Inc. | Methods and compositions for preventing or treating calciphylaxis |
| MX2020013302A (es) | 2018-06-08 | 2021-05-12 | Epizon Pharma Inc | Métodos y composiciones para prevenir o tratar calcificación de tejido. |
| US10822295B2 (en) | 2018-09-12 | 2020-11-03 | Epizon Pharma, Inc. | Menaquinol compositions and methods of treatment |
| EP3890831A4 (en) * | 2019-01-04 | 2022-09-21 | Kaydence Pharma AS | COMBINATION THERAPY OF PHOSPHATE BINDERS AND VITAMIN K |
| CN112691058A (zh) * | 2020-12-31 | 2021-04-23 | 玉溪健坤生物药业有限公司 | 一种含还原型维生素k2的牙膏及其制备方法 |
| CN114748486A (zh) * | 2022-03-25 | 2022-07-15 | 南京盛德生物科技研究院有限公司 | 一种含有维生素k2改善心血管钙化的药物组合物及其制备方法与应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050176778A1 (en) | 2001-08-03 | 2005-08-11 | Vitak Bv | Isoprenyl derivatives and their use in the title treatment and prevention of osteoporosis and cardiovascular calcification |
| WO2005030190A1 (en) | 2003-09-26 | 2005-04-07 | Natural Asa | Natural menaquinone 7 compositions |
| DE602006020658D1 (de) | 2005-06-03 | 2011-04-28 | Nattopharma Asa | Verwendung von Vitamin K, um die Verkalkung der Blutgefässe rückgängig zu machen |
| WO2007095630A2 (en) | 2006-02-15 | 2007-08-23 | The Regents Of The University Of California | New ubiquinone analogs and methods of use |
| NZ574882A (en) * | 2006-07-14 | 2012-08-31 | Nattopharma Asa | Pharmaceutical and nutraceutical products comprising vitamin k2 |
| GB0817528D0 (en) | 2008-09-24 | 2008-10-29 | Syntavit As | Process |
| BR112013009724A2 (pt) | 2010-11-01 | 2016-07-19 | Viridis Biopharma Pvt Ltd | equilíbrio dinâmico do sistemna nervoso autonômo utilizando a vitamina mk-7 |
| GB201203705D0 (en) | 2012-03-02 | 2012-04-18 | Kappa Bioscience As | Prodrugs |
| US10159787B2 (en) | 2012-06-18 | 2018-12-25 | Fresenius Kabi Deutschland Gmbh | Port cannula system for puncturing port catheters |
| WO2014191466A1 (en) | 2013-05-28 | 2014-12-04 | Nattopharma Asa | Menaquinone supplementation and vascular health |
| GB201314245D0 (en) | 2013-08-08 | 2013-09-25 | Kappa Bioscience As | Provitamins |
| EP2868658B1 (en) | 2013-11-01 | 2018-05-02 | Dilip Mehta | Method of preparation of stereospecific quinone derivatives |
| EP3258924A2 (en) * | 2015-02-20 | 2017-12-27 | VitaK B.V. | Vitamin k and capillary function |
| BR112017019750A2 (en) | 2015-03-20 | 2018-05-29 | Gnosis S.P.A. | process for preparing a crystalline form of menaquinol, crystalline form of menaquinol, process for preparing a solid form of menaquinol, pharmaceutical or nutraceutical composition and use of the crystalline form of menaquinol |
| CN206387961U (zh) | 2016-12-30 | 2017-08-08 | 孙淑芬 | 头戴显示设备 |
| IT201700085412A1 (it) * | 2017-07-26 | 2019-01-26 | Pharmanutra S P A | Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare |
| US10368858B1 (en) | 2018-01-25 | 2019-08-06 | Ring Orthopedics, Inc. | Suture passer |
| EP3774707A1 (en) | 2018-04-06 | 2021-02-17 | Instytut Farmaceutyczny | Process of vitamin k 2 derivatives preparation |
| MX2020013302A (es) | 2018-06-08 | 2021-05-12 | Epizon Pharma Inc | Métodos y composiciones para prevenir o tratar calcificación de tejido. |
| WO2019237054A1 (en) | 2018-06-08 | 2019-12-12 | Epizon Pharma, Inc. | Methods and compositions for preventing or treating calciphylaxis |
| US10822295B2 (en) | 2018-09-12 | 2020-11-03 | Epizon Pharma, Inc. | Menaquinol compositions and methods of treatment |
-
2019
- 2019-06-07 WO PCT/US2019/036139 patent/WO2019237054A1/en not_active Ceased
- 2019-06-07 EP EP19814419.8A patent/EP3801478A4/en active Pending
- 2019-06-07 JP JP2021518057A patent/JP2021527129A/ja active Pending
- 2019-06-07 AU AU2019282421A patent/AU2019282421B2/en active Active
- 2019-06-07 CA CA3102979A patent/CA3102979A1/en active Pending
- 2019-06-07 MX MX2020013301A patent/MX2020013301A/es unknown
- 2019-06-07 US US16/435,230 patent/US10736858B2/en active Active
- 2019-06-07 CN CN201980052691.0A patent/CN112955131A/zh active Pending
- 2019-06-07 KR KR1020217000119A patent/KR20210018422A/ko active Pending
- 2019-06-07 SG SG11202012055PA patent/SG11202012055PA/en unknown
-
2020
- 2020-06-16 US US16/902,705 patent/US11065212B2/en active Active
- 2020-06-16 US US16/902,709 patent/US10987320B2/en active Active
- 2020-06-16 US US16/902,701 patent/US10925838B2/en active Active
- 2020-07-31 US US16/944,479 patent/US10940123B2/en active Active
- 2020-12-06 IL IL279246A patent/IL279246B2/en unknown
- 2020-12-07 MX MX2024010211A patent/MX2024010211A/es unknown
-
2021
- 2021-06-16 US US17/349,663 patent/US11793773B2/en active Active
-
2023
- 2023-08-07 US US18/231,035 patent/US12433854B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20240041794A1 (en) | 2024-02-08 |
| US20200306207A1 (en) | 2020-10-01 |
| EP3801478A1 (en) | 2021-04-14 |
| IL279246B1 (en) | 2023-04-01 |
| EP3801478A4 (en) | 2022-02-23 |
| US20210378987A1 (en) | 2021-12-09 |
| KR20210018422A (ko) | 2021-02-17 |
| MX2024010211A (es) | 2024-09-02 |
| US20200360301A1 (en) | 2020-11-19 |
| IL279246B2 (en) | 2023-08-01 |
| IL279246A (en) | 2021-01-31 |
| US20200306208A1 (en) | 2020-10-01 |
| CN112955131A (zh) | 2021-06-11 |
| US12433854B2 (en) | 2025-10-07 |
| JP2021527129A (ja) | 2021-10-11 |
| AU2019282421B2 (en) | 2025-01-09 |
| US11065212B2 (en) | 2021-07-20 |
| SG11202012055PA (en) | 2021-01-28 |
| US11793773B2 (en) | 2023-10-24 |
| US10940123B2 (en) | 2021-03-09 |
| AU2019282421A1 (en) | 2021-01-07 |
| WO2019237054A1 (en) | 2019-12-12 |
| US20200306206A1 (en) | 2020-10-01 |
| US10925838B2 (en) | 2021-02-23 |
| US20190374483A1 (en) | 2019-12-12 |
| US10736858B2 (en) | 2020-08-11 |
| US10987320B2 (en) | 2021-04-27 |
| CA3102979A1 (en) | 2019-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020013301A (es) | Metodos y composiciones para prevenir o tratar calcifilaxis. | |
| MX2024013515A (es) | Metodos y composiciones para prevenir o tratar calcificacion de tejido | |
| PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| PH12015502275B1 (en) | Therapuetic uses of empagliflozin | |
| EA201500997A1 (ru) | Терапевтические применения эмпаглифлозина | |
| MX2017010734A (es) | Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos. | |
| CL2019001927A1 (es) | Composiciones y métodos para el tratamiento de la anemia (divisional solicitud 201702456). | |
| MX2022002504A (es) | Anticuerpos para cd40. | |
| PH12015502310A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| EP4417255A3 (en) | Compositions and methods for treating pulmonary hypertension | |
| EA201400119A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| PH12018502593A1 (en) | Combinations of linagliptin and metformin | |
| JOP20170128A1 (ar) | عوامل ارتباط عكسية للأجسام المضادة الموجهة ضد عامل التجلط XI/XIa واستخداماتها | |
| EA201591806A1 (ru) | Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител | |
| EP4570314A3 (en) | Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure | |
| MX357941B (es) | Serpinas modificadas para el tratamiento de trastornos de la coagulacion. | |
| CA2947310C (en) | Microparticles for treating renal cell carcinoma | |
| MX2019014090A (es) | Métodos para el tratamiento de la reservoritis crónica. | |
| MX2022000394A (es) | Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer. | |
| MX2021004174A (es) | Sistema y método para eliminar toxinas uremicas del cuerpo del paciente. | |
| BR112015025438A2 (pt) | silicato de zircónio e diuréticos microporosa para a redução de potássio e de tratamento renal crônico e / ou doença cardíaca crônica | |
| BR112015023390A2 (pt) | métodos para tratar de doença renal e outros distúrbios | |
| WO2021034293A3 (en) | Multiple perfusion cannula system for use in aortic surgery | |
| MX2021011044A (es) | Agentes de union a potasio para su uso en pacientes de hemodialisis. | |
| EA201790868A1 (ru) | 1,2-бензотиазольные соединения для лечения почечного расстройства |